Saturday 17 October 2026
Export NEXI’s income statement to Excel — free account
NexImmune, Inc.
NEXI Healthcare Biotechnology
Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow NEXI
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Trend | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 100.25 | 4.87 | 1.25 |
Analyst estimates 2024–2026 Powerpack |
|||
| High | — | — | — | — | — | — | — | 700.00 | 122.75 | 20.35 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 44 | 74 | 50 | 6 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | |||||
| EBT | — | — | — | — | (13) | (21) | (30) | (51) | (63) | (32) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | 0 | (13) | (21) | (30) | (51) | (63) | (32) | |||||
| Depreciation | — | — | — | — | 0 | 0 | 1 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | (16.55) | (414.09) | (660.50) | (63.50) | (65.00) | (30.82) | |||||
| Cash flow | — | — | — | — | (12.34) | (391.44) | (525.99) | (56.71) | (53.19) | (29.95) | |||||
| Capex | — | — | — | — | 0.00 | (25.12) | (17.23) | (2.91) | (1.22) | (0.04) | |||||
| Free cash flow | — | — | — | — | (12.34) | (416.56) | (543.22) | (59.62) | (54.41) | (29.99) | |||||
| Book value | — | — | — | — | (26.90) | (867.13) | (1,381.97) | 103.74 | 33.56 | 3.34 | |||||
| Shares, m | — | — | — | — | 1 | 0 | 0 | 1 | 1 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (11) | (19) | (26) | (46) | (51) | (31) | ||||
| Capex | — | — | — | — | (1) | (1) | (1) | (2) | (1) | 0 | |||||
| Free cash flow | — | — | — | — | (11) | (21) | (27) | (48) | (52) | (31) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 9 | 8 | (19) | 79 | 27 | 0 | ||||
| Total debt | — | — | — | — | 35 | 54 | 19 | — | 1 | — | |||||
| Net debt | — | — | — | — | 23 | (10) | 14 | (82) | (35) | (3) | |||||
| Shareholders’ equity | — | — | — | — | (24) | (43) | (69) | 84 | 32 | 4 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (210.81) | (166.59) | (264.97) | (100.22) | (93.23) | (125.24) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | (1,775.29) | 0.00 | (7,175.66) | |||||
| ROE | — | — | — | — | 44.33 | 69.02 | 58.99 | (712.92) | (107.71) | (180.64) | |||||
Negative figures in brackets.
Charts ten years each
NexImmune, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SILO Silo Pharma, Inc. | $1.9M | — (loss-making) | 18.4× | 0.00% | n/m | +39.17% (above 0%: growing) | (15.00%) | 0.00% | Compare |
| GNPX GENPREX | $1.9M | 0.0× | — | — | n/m | −32.98% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| TRVN Trevena, Inc. | $1.8M | — (loss-making) | — (loss-making) | +57.22% (above 0%: growing) | n/m | +49.55% (above 0%: growing) | 59.72% | (1,970.67%) | Compare |
| NEXI NexImmune, Inc. | $1.6M | — (loss-making) | — | — | n/m | +66.38% (above 0%: growing) | 0.00% | 0.00% | |
| ITRMF Iterum Therapeutics PLC | $1.6M | — (loss-making) | — (loss-making) | +110.81% (above 0%: growing) | n/m | −179.15% (below 0%: shrinking) | 94.87% | (1,982.31%) | Compare |
| CARM Carisma Therapeutics Inc. | $1.5M | — (loss-making) | — (loss-making) | +392.01% (above 0%: growing) | n/m | +114.65% (above 0%: growing) | 100.00% | 96.83% | Compare |
| ARTL Artelo Biosciences, Inc. | $1.5M | — (loss-making) | — | — | n/m | −879.18% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ABPO Abpro Holdings Inc. | $1.4M | 0.2× | — | — | n/m | −0.48% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MLEC Moolec Science SA | $1.4M | — (loss-making) | — (loss-making) | +948.39% (above 0%: growing) | n/m | +4.48% (above 0%: growing) | (25.52%) | (77.92%) | Compare |
| Median of peers | $1.6M | — | — | +110.81% | — | +2.00% | 29.86% | 0.00% |
NexImmune, Inc. (NEXI) Latest News
No news at this impact. Lower the threshold for more.